GE Healthcare, a subsidiary of American multinational conglomerate General Electric, completed the acquisition of Zionexa, an innovative company developing and commercializing molecular imaging solutions. Financial terms were not disclosed. “Like GE Healthcare, Zionexa’s products are aimed at enabling more precise diagnosis, improved treatment decision-making and ultimately better clinical outcomes for patients. This acquisition further demonstrates our commitment to enabling precision health and providing innovations that support oncologists, nuclear medicine specialists and other physicians throughout a cancer patient’s journey, from initial screening and diagnosis to informing therapy selection and monitoring the effectiveness of treatment," Kevin O’Neill, GE Healthcare President and CEO.